851337-37-6

Basic information

• Product Name: 2-(4-fluorophenyl)cyclohexanol
• Synonyms: 2-(4-fluorophenyl)cyclohexanol
• CAS NO: 851337-37-6
• Molecular Formula: C₁₂H₁₅FO
• Molecular Weight: 194.2453032
• Mol File: 851337-37-6.mol

Chemical Properties

• Boiling Point: 294.3°C at 760 mmHg
• Flash Point: 147.8°C
• Appearance: /
• Density: 1.13g/cm³
• Vapor Pressure: 0.000745mmHg at 25°C
• Refractive Index: 1.537
• CAS DataBase Reference: 2-(4-fluorophenyl)cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluorophenyl)cyclohexanol(851337-37-6)
• EPA Substance Registry System: 2-(4-fluorophenyl)cyclohexanol(851337-37-6)

Safety Data

• Hazardous Substances Data: 851337-37-6(Hazardous Substances Data)

Usage

Physical state

White solid

Synthesis

Used in the synthesis of various pharmaceuticals and organic compounds

Primary use

Intermediate in the production of other chemicals

Potential applications

Pharmaceutical industry for the development of new drugs

Medical properties

Mild analgesic and anti-inflammatory properties

Potential medical uses

Of interest for potential medical uses

Chiral ligand

Studied for its potential use as a chiral ligand in asymmetric catalysis

Industries of use

Pharmaceutical and chemical industries

InChI:InChI=1/C12H15FO/c13-10-7-5-9(6-8-10)11-3-1-2-4-12(11)14/h5-8,11-12,14H,1-4H2

Upstream product

• 286-20-4 cyclohexane-1,2-epoxide 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 108-94-1 cyclohexanone 
• 1493-23-8 (4-fluorophenyl)lithium 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 1316848-57-3 2-(4-fluorophenyl)-1-(trimethylsiloxy)cyclohex-1-ene 
• 1375500-75-6 {4-[2-(4-fluoro-phenyl)-cyclohex-1-enyl]-pyridin-2-yl}-urea 
• 1375502-12-7 4-[2-(4-fluoro-phenyl)-cyclohex-1-enyl]-pyridin-2-ylamine 
• 1375502-08-1 2-chloro-4-[2-(4-fluoro-phenyl)-cyclohex-1-enyl]-pyridine 
• 1375502-06-9 trifluoro-methanesulfonic acid 2-(4-fluoro-phenyl)-cyclohex-1-enyl ester 
• 59227-02-0 rac-2-(4-fluorophenyl)cyclohexan-1-one 

Relevant articles and documents

The Silicon-Hydrogen Exchange Reaction: Catalytic Kinetic Resolution of 2-Substituted Cyclic Ketones

We have recently reported the strong and confined, chiral acid-catalyzed asymmetric 'silicon-hydrogen exchange reaction'. One aspect of this transformation is that it enables access to enantiopure enol silanes in a tautomerizing σ-bond metathesis, via deprotosilylation of ketones with allyl silanes as the silicon source. However, until today, this reaction has not been applied to racemic, 2-substituted, cyclic ketones. We show here that these important substrates readily undergo a highly enantioselective kinetic resolution furnishing the corresponding kinetically preferred enol silanes. Mechanistic studies suggest the fascinating possibility of advancing the process to a dynamic kinetic resolution.

Method for preparing alcohol through reaction of Suzuki no exogenous alkali (by machine translation)

The method for synthesizing the alcohol compound by. using the method disclosed by the invention for preparing .the alcohol compound by adopting the method Suzuki disclosed by the invention has the advantages that the reaction system, is convenient and convenient, to prepare, and the reaction system is convenient to prepare . Suzuki. (by machine translation)

Aromatic compound, preparation method and use of aromatic compound

The invention relates to an aromatic compound, a preparation method and use of the aromatic compound, andspecifically discloses a compound represented by the following formula (I), or a tautomer or anenantiomer or a diastereomer or a racemate of the compound or a mixture of the compound or a pharmaceutically acceptable salt of the compound. The invention further discloses a preparation method ofthe compound and application of the compound in treating nervous systemdiseases.

p-Toluenesulfonic acid catalysed fluorination of α-branched ketones for the construction of fluorinated quaternary carbon centres

A p-toluenesulfonic acid catalyzed fluorination of α-branched ketones for the construction of fluorinated quaternary carbon centers has been developed, featuring a broad substrate scope, environmentally benign reaction conditions, and operational simplicity.

Construction of a chiral quaternary carbon center by catalytic asymmetric alkylation of 2-arylcyclohexanones under phase-transfer conditions

In this paper, we present an asymmetric alkylation of modified 2-arylcyclohexanones that employs a novel chiral ammonium bromide as a phase-transfer catalyst and an achiral auxiliary as a controller to improve the enantioselectivity to afford optically enriched products having a chiral quaternary carbon center.

PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS

Mineralocorticoid receptor antagonists, of which formula (1) is exemplary.

Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors

Screening of the Roche compound library led to the identification of cis-N-(2-phenyl-cyclohexyl)-spiropiperidine 1 as structurally novel GlyT1 inhibitor. The SAR, which was developed in this series, resulted in the discovery of highly potent compounds displaying excellent selectivity against the GlyT2 isoform.

Diaza-spiropiperidine derivatives

The present invention relates to compounds of formula wherein A-B is —CH2—CH2—, —CH2—O— or —O—CH2—; X is hydrogen or hydroxy; R1 is aryl, optionally substituted by one or two substituents selected fro

TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

The invention relates to compounds of the general formula (I), wherein A-A is -CH2-CH2-, -CH2-CH2-CH2-, -CH2-0- or -0-CH2-; x is hydrogen or hydroxy; R1 is aryl or heteroaryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl; R2 is aryl or heteroaryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl, or is lower alkyl, -(CH2)n--cycloalkyl, -(CH2)n-CF3, -(CH2)p-0-lower alkyl, -(CH2)1,2-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy or trifluoromethyl, or is -(CH2)p-NRR", wherein W and R" form together with the N-atom a heterocyclic ring, selected from the group consisting of piperidine, morpholine, thiomorpholine or 1, I-dioxo thiomorpholine; R3, R4 are independently from each other hydrogen, lower alkyl, phenyl or benzyl; R5 is hydrogen, lower alkyl or benzyl; R6 is hydrogen or lower alkyl; n is 0, 1 or 2; and p is 2 or 3; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

2,10-Disubstituted dibenzo[b,d]pyrans and benzo[c]quinolines

A compound of the formula STR1 wherein Q is CH2, C=O, CHOH or CHCH2 OH; M is O or NR6 ; where R6 is hydrogen, or certain alkyl, aralkyl, acyl or carboalkoxy substituted alkyl groups; R1 is hydrogen, or certain alkanoyl or amino substituted alkanoyl groups; R4 and R5 are each hydrogen or alkyl having from 1 to 4 carbon atoms; Z is alkylene having from 1 to 9 carbon atoms or --(alk1)--X--(alk2)n -- where (alk1) and (alk2) are certain alkylene groups and X is O, S, SO or SO2 ; W is a methyl, phenyl, substituted phenyl, pyridyl, piperidyl, cycloalkyl or substituted cycloalkyl group and the pharmaceutically acceptable and addition salts of said compounds having a basic nitrogen atoms. Said compounds are useful as analgesics and as intermediates therefore.